BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Europabio X-ORIGINAL-URL:https://www.europabio.org X-WR-CALDESC:Events for Europabio REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Europe/Brussels BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20210328T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20211031T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20220327T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20221030T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20230326T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20231029T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20240331T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20241027T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230926T100000 DTEND;TZID=Europe/Brussels:20230928T190000 DTSTAMP:20260526T180902 CREATED:20230320T145053Z LAST-MODIFIED:20230320T145327Z UID:6038-1695722400-1695927600@www.europabio.org SUMMARY:BIOSPAIN 2023 DESCRIPTION:BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings and companies participating. 34% of our delegates came from outside of Spain. \n\n\n\nThis year\, BIOSPAIN goes back to Barcelona\, the main biotech cluster in Spain and one of the most dynamic cities in the world. \n\n\n\nThe event will take place in Pavilion 1 – Fira de Barcelona – Montjuïc. It stands in a superb location in the city center\, easily accessible from the airport and well-connected to the public transport network. It is located in Montjuïc Park\, an area of cultural and historical interest thanks to its museums and theatres and it also features some of the main tourist attractions in Barcelona. \n\n\n\n\nMore information URL:https://www.europabio.org/event/biospain-2023/ CATEGORIES:External,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230925T120000 DTEND;TZID=Europe/Brussels:20230925T131500 DTSTAMP:20260526T180902 CREATED:20230710T072650Z LAST-MODIFIED:20230925T072852Z UID:6450-1695643200-1695647700@www.europabio.org SUMMARY:The economic power of biotechnology for Europe DESCRIPTION:The world is at a key point of industrial and societal transition\, driven by advancing technology and the need for competitive\, resilient and sustainable economies. \n\n\n\nBiotechnology is at the heart of this transition across all sectors and it is playing a significant role in shaping Europe’s future. \n\n\n\nEuropean Biotech Week kick starts with a look at how biotechnology performs in the European Union’s economy. \n\n\n\nProfessor Dennis Ostwald\, founder and CEO of the WifOR Institute presents the 2023 edition of EuropaBio’s ‘Measuring the economic footprint of the biotechnology industry in Europe’. Professor Ostwald showcases how biotechnology contributes across healthcare and industrial sectors in the light of Europe’s response to Covid\, global supply chains stressed further by the Russian invasion of Ukraine\, and at a time when Europe also has ambitious climate change goals. \n\n\n\nSpeakers: \n\n\n\nProfessor Dr. Dennis A. Ostwald. Through his studies\, Prof. Ostwald aims to make the importance of health innovations visible and enable evidence-based decision making for a healthy society. He conducts research on topics such as health economics\, the value of impacts\, and international social policy. Prof. Ostwald studied Industrial Engineering and Management at the Technical University of Darmstadt\, Germany and received his PhD from the Chair of Finance and Economic Policy\, Prof. Dr. Dr. h.c. Bert Rürup\, on the topic “Growth and employment effects of the healthcare industry”. As Professor of Economic Research and International Management at the Steinbeis School of International Business and Entrepreneurship (SIBE)\, he wants to develop young talents into responsible managers who understand the interplay between social\, environmental and economic sustainability.  \n\n\n\n \n\n\n\nJoin EuropaBio to understand how biotechnology is increasing its role with Europe’s economy and discuss with Members what this means for sectors\, countries and citizens. \n\n\n\n\nRegister here URL:https://www.europabio.org/event/the-economic-power-of-biotechnology-for-europe/ CATEGORIES:Biotech Week ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/07/GENERAL-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230920T080000 DTEND;TZID=Europe/Brussels:20230921T170000 DTSTAMP:20260526T180902 CREATED:20230615T070358Z LAST-MODIFIED:20230615T070523Z UID:6387-1695196800-1695315600@www.europabio.org SUMMARY:Life Sciences Baltics as a contributor to Lithuania’s innovation ecosystem DESCRIPTION:Life sciences in Lithuania have been a priority for the government for over a decade. Accelerating faster than almost anywhere else in Europe\, the sector aims to contribute 5% to Lithuania’s GDP by 2030. The close cooperation between actors of the ecosystem is one of the reason for success.   \n\n\n\nCreative collaboration takes place in Lithuania’s innovation ecosystem in a variety of ways\, including events\, cross-promotion\, and sharing of resources. The leading life sciences Baltics event in the region – Life Sciences Baltics – is one of the best examples of these collaborations. \n\n\n\nSince its initiation in 2012\, the forum has aimed to create as many opportunities as it is possible for deeper cooperation between the growing life sciences ecosystems in the Baltics and international partners. \n\n\n\nHeld every two years\, the forum has grown from a 300-person assembly to a community of up to 800 key participants from around 40 countries: corporate CEOs\, startup founders\, tech scouts\, investors\, researchers. It is the largest life sciences event in the Eastern and Central Europe. \n\n\n\nThe event will take place in the Lithuania’s capital city of Vilnius on September 20-21. The pre-registration is already open for participants and exhibitors. \n\n\n\nWhether there is a need to kick off the project\, generate leads\, or engage in valuable partnerships\, Life Sciences Baltics offers a diverse range of interactions for its participants: international conference\, exhibition\, networking spaces\, pitch challenge for startups. \n\n\n\nIt also hosts business delegations and offers an opportunity for side visits to Lithuania’s organizations and institutions. \n\n\n\nThe program of the international conference is divided into sessions with the most trending topics worldwide that are also breakthrough areas in the Baltic countries: gene editing\, CRISPR diagnostics\, AI and digital health innovations\, nanomedicine\, microbiome\, reinvention of clinical trials\, digital biomarkers and many more. \n\n\n\nMany big names have attended Life Sciences Baltics\, among them Thermo Fisher Baltics\, Johnson&Johnson\, Clarivate\, Novartis\, Abbvie\, AstraZeneca\, and others. Nobel prize winners Richard Henderson\, Brian Kobilka\, Dan Shechtman\, CRISPR pioneer Prof. Dr Virginijus Šikšnys were among top conference speakers. \n\n\n\nThe event will keep tabs on the fastest growing startups in the region\, but only 10 hand-picked startups will have an opportunity to showcase who they are in front of a panel of investors. \n\n\n\nThe event is organized by Innovation Agency Lithuania\, an official public agency responsible for the Lithuanian innovation ecosystem and is supported by Lithuania’s local ecosystem actors – Lithuanian biotechnology association\, universities\, hospitals\, business angels and Lithuania’s life sciences enthusiasts.  \n\n\n\nThe Baltics\, and Lithuania in particular\, – the next big thing in life sciences  \n\n\n\nLife Sciences Baltics make it possible to assess the attractiveness of the Baltic countries in close-up – Estonia\, Latvia and Lithuania show their distinct\, but strong potential in the sector. \n\n\n\nThree Baltic countries are particularly seeing a growth in life sciences startups. While average funding per startup is decreasing globally\, it’s increasing in the region.  Lithuania attracts growing VC interest into global solutions produced by local entrepreneurs and scientists. \n\n\n\nFocused on nurturing the next generation of talents\, the local life sciences enterprises in the Baltics excel at creativity and entrepreneurship. In 2021 alone\, Lithuania’s life sciences sector grew by almost 87% and generated revenues of 2 billion euros. \n\n\n\n90% of the output of Lithuania’s life sciences are exported to more than 100 countries worldwide. Lithuanian-made medical and pharmaceutical equipment and other products are trusted by customers in the USA\, Germany\, France\, and elsewhere. \n\n\n\nOne of the most prominent players in Lithuania is Thermo Fisher Scientific Baltics\, which has stimulated the development of Lithuania’s industry during the last decade. This company\, along with other international players in the market\, work with local actors for various R&D projects and supply chain. \n\n\n\n\nFor more details URL:https://www.europabio.org/event/life-sciences-baltics-as-a-contributor-to-lithuanias-innovation-ecosystem/ CATEGORIES:External ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/06/Event-Banners-Website-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230704T100000 DTEND;TZID=Europe/Brussels:20230704T170000 DTSTAMP:20260526T180902 CREATED:20230614T151559Z LAST-MODIFIED:20230614T151749Z UID:6377-1688464800-1688490000@www.europabio.org SUMMARY:Industrial Biotechnologies Day DESCRIPTION:CEFIC Specialty Chemicals sector groups EFCG\, Biochem Europe and EFG\, together with SICOS\, the French industry association for Fine Chemicals and Biotech\, will jointly hold their first in-person Industrial Biotechnologies Day on July 4th\, 2023 in Brussels. \n\n\n\nSpecialists from the industry\, EU policy makers\, and civil society will come together across four panels to dive into topics such as: \n\n\n\n\nEuropean policies shaping the biotech landscape – what is needed to unleash its full potential?\n\n\n\nEuropean regulatory frameworks – an obstacle to innovation?\n\n\n\nFeedstocks and industrial capacities – what is the role of energy costs?\n\n\n\nNew technologies and future breakthroughs – what to expect and what’s at stake?\n\n\n\n\nConfirmed Speakers: \n\n\n\n\nHans Ingels\, European Commission – Directorate-General for Internal Market\, Industry\, Entrepreneurship and SMEs\n\n\n\nLudo Diels\, Flemish Institute for Technological Research (VITO)\n\n\n\nVincent Touraille\, Sicos\n\n\n\nKarel De Winter\, Bio Base Europe Pilot Plant\n\n\n\nMarcello Buson\, Olon SpA\n\n\n\nFrédéric Van Gansberghe\, Futerro\n\n\n\nClaire Skentelberry\, Europabio\n\n\n\nChristian Le Roux\, Group M21\n\n\n\nHarald Ruissenaars\, Corbion\n\n\n\nEric Bierny\, Galactic\n\n\n\nNicolas Martin\, Metex\n\n\n\nThomas Canova\, Solvay\n\n\n\nJulien Honoré\, Roquette\n\n\n\nJuliette Martin\, Seqens\n\n\n\nGwenaël Servant\, Abolis\n\n\n\n\n\nMore details URL:https://www.europabio.org/event/industrial-biotechnologies-day/ CATEGORIES:External ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/06/Event-Banners-Website.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230630T124500 DTEND;TZID=Europe/Brussels:20230630T124500 DTSTAMP:20260526T180902 CREATED:20230321T210403Z LAST-MODIFIED:20230321T210405Z UID:6074-1688129100-1688129100@www.europabio.org SUMMARY:DUTCH BIOTECH EVENT 2023 DESCRIPTION:Join us to celebrate the power of biotech at the Dutch Biotech Event 2023! \n\n\n\nAbout HollandBIO’s Dutch Biotech Event \n\n\n\nThe program features inspiring talks by keynote speakers on biotech and entrepreneurship\, followed by workshops and break-out sessions that contribute to your personal development and that of your company. In addition\, there will be plenty of opportunities for networking during the break\, drinks and vegetarian BBQ. \n\n\n\nWho can join Dutch Biotech Event? \n\n\n\nThe Dutch Biotech Event welcomes HollandBIO members (registration free of charge) and employees of other biotech R&D companies (registration fee €295\,- p.p.)\, with a maximum of 2 delegates per organization. \n\n\n\nWe invite non-member startups to consider a HollandBIO membership (€562\,-/year)\, which besides access to the network & events\, offers many more advantages. \n\n\n\n\nMore information URL:https://www.europabio.org/event/dutch-biotech-event-2023/ LOCATION:Inn Style\, Herenweg 55\, Maarssen\, 3602 AN\, Netherlands CATEGORIES:External,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230627T180000 DTEND;TZID=Europe/Brussels:20230627T200000 DTSTAMP:20260526T180902 CREATED:20230524T142640Z LAST-MODIFIED:20230616T172415Z UID:6330-1687888800-1687896000@www.europabio.org SUMMARY:NAC Spanish Presidency Summer Reception DESCRIPTION:EuropaBio\, and AseBio\, the Spanish Association of Biotechnology Companies\, with the support of Merck\, will host a summer reception to mark the beginning of the Spanish Council Presidency of the European Union and present the outcomes of their National Association Council Presidency Summit.  \n\n\n\nThe event will take place on June 27th in Brussels at Comet Meetings – Louise\, from 18-20h. If you wish for more details\, please get in touch with José Peres at j.peres@europabio.org  URL:https://www.europabio.org/event/nac-spanish-presidency-summer-reception/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/NAC-Summer-Reception-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230627T140000 DTEND;TZID=Europe/Brussels:20230627T160000 DTSTAMP:20260526T180902 CREATED:20230516T093527Z LAST-MODIFIED:20230517T184028Z UID:6244-1687874400-1687881600@www.europabio.org SUMMARY:Reflection seminar and closing party around the EU presidency DESCRIPTION:On June 27\, a Life Science conference is arranged for EU parliamentarians during Sweden’s EU presidency. \n\n\n\nDirectly after the official conference\, The Royal Academy of Engineering Sciences (IVA) and SwedenBIO invites the public to a seminar with the spotlight on how the suggested EU legislations may affect the life science industry. With examples from the Swedish life science arena\, we show the importance of intellectual property and data protection in the journey from academic research to products and therapies for patients. \n\n\n\nAfterward\, a networking reception is organized by the united life science industry organisations. With drinks\, snacks\, and key speakers\, we ensure that the end of the presidency marks the start of an even stronger united life science industry in Sweden and beyond. \n\n\n\n\nMore details URL:https://www.europabio.org/event/reflection-seminar-and-closing-party-around-the-eu-presidency/ LOCATION:IVA Conference Center\, Grev Turegatan 15\, Stockholm\, Sweden CATEGORIES:External ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230622T140000 DTEND;TZID=Europe/Brussels:20230622T160000 DTSTAMP:20260526T180902 CREATED:20230414T130232Z LAST-MODIFIED:20230621T083523Z UID:6128-1687442400-1687449600@www.europabio.org SUMMARY:EuropaBio National Associations Council Summit 2023 (Spanish Presidency): A global Europe - the role of transformative legislation DESCRIPTION:Spain will hold the Presidency of the Council of the European Union for the fifth time in the second half of 2023\, between July 1 and December 31. In a pivotal time for the Biotechnology industry\, Spain will lead the dialogue on the European Commission’s proposal on new genomic techniques (NGT) and the revision of the Pharmaceutical Strategy for Europe – critical policies for European patients\, Europe’s food security and the green transition. \n\n\n\nEuropaBio – the European Association for Bioindustries and AseBio\, the Spanish Association of Biotechnology Companies\, are proud hosts of EuropaBio’s National Associations Council (NAC) annual Presidency Summit. Invited speakers from industry\, policymakers\, and national biotechnology associations will explore the latest policy developments and offer their insights into the upcoming work and ambitions of the Spanish Council Presidency. \n\n\n\nThe Summit will be public and held online on June 22. The event will be followed by a Summer reception on June 27 in Brussels to present our participants’ key messaging and recommendations. \n\n\n\nIf you wish to attend our session or have any questions\, insights or suggestions\, please do not hesitate to reach José Peres at j.peres@europabio.org. \n\n\n\nAgenda \n\n\n\nOpening remarks \n\n\n\n\nTineke Van hooland\, Deputy Secretary General at bio.be/essenscia\, Chair of the National Associations Council (NAC) at EuropaBio\n\n\n\n\nPanel I: Innovation for European Patients: the European pharmaceutical legislation \n\n\n\n\nMEP Dolors Montserrat (EPP)\n\n\n\nAna Polanco\, AseBio Chair of the Board\, Head of European Government and Public Affairs\, and Market Access and Pricing at Merck\n\n\n\nDr Jessica Martinsson\, Director General at SwedenBio\n\n\n\nMaria Pascual\, Chief Regulatory Officer at Minoryx Therapeutics\n\n\n\nModeration: Vlad Olteanu\, Healthcare Public Affairs Director at EuropaBio\n\n\n\n\nPanel II: Resilience\, sustainability and competitiveness for Europe’s food chain: new genomic techniques \n\n\n\n\nIlaria Ciabatti\, Team Leader Biotechnology Unit\, European Commission DG Santé\n\n\n\nIon Arocena Vélez\, Director General at AseBio – the Spanish Association of Biotechnology Companies\n\n\n\nElke Duwenig\, Senior Expert Global Regulatory / Public & Government Affairs Biotechnology\, Nutrition & Health at BASF\n\n\n\nOana Dima\, Executive Manager of the EU-SAGE network\, Science Policy Manager at VIB-Ghent University Center for Plant Systems Biology\n\n\n\nTomasz Zimny\, Assistant Professor at the Institute of Law Studies\, Polish Academy of Sciences\, Warszawa\, Poland\n\n\n\nAna Judith Martín de la Fuente\, Head of Area/Secretary of the Interministerial Council of GMOs at the Spanish Ministry of Agriculture\, Food and Fisheries\n\n\n\nModeration: Anne-Gaelle Collot\, Industrial Biotechnology Director at EuropaBio\n\n\n\n\nClosing remarks \n\n\n\n\nClaire Skentelbery\, Director General at EuropaBio\n\n\n\n\n \n\n\n\n\nRegister here URL:https://www.europabio.org/event/europabio-national-associations-council-summit-2023-spanish-presidency-a-global-europe-the-role-of-transformative-legislation/ ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/04/NAC-SUMMIT-BANNER-V2A.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230616T083000 DTEND;TZID=Europe/Brussels:20230616T100000 DTSTAMP:20260526T180902 CREATED:20230524T085454Z LAST-MODIFIED:20230524T142847Z UID:6326-1686904200-1686909600@www.europabio.org SUMMARY:GREEK BIOPHARMA INNOVATION: Your changing world with the new EU Pharma Legislation DESCRIPTION:Chairperson: Claire Skentelbery\, Director General EuropaBio \n\n\n\nParticipants: \n\n\n\nKostas Papagiannis Country President & Managing Director Novartis Greece \n\n\n\nHardy Rideout Anacalypsis Therapeutics \n\n\n\nGeorge Drakakis CEO PurposefulEU pharma legislation is going to change your business. What you make\, where and how you sell it\, and whether your business model is even viable.The European Commission published new legislative proposals in April that will redefine the business model of biotechnology in Europe. In trying to bring medicines to more patients\, the legislation proposals reduce data protection\, limit exclusivity for orphan medicines and brings heavy pressure to launch in all 27 Member States within two years of EMA approval.Changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, those seeking scale up investment\, clinical trials and companies going to market\, often for the first time.This session/panel\, chaired by EuropaBio\, presents the key impacts points for biotechnology innovation within Greece\, with contributions from small and large companies and policy makers – bring your voice to the discussion for the future of your own science. \n\n\n\n\nMore information URL:https://www.europabio.org/event/greek-biopharma-innovation-your-changing-world-with-the-new-eu-pharma-legislation/ LOCATION:Megaron Athens International Conference Centre\, Athens\, Greece CATEGORIES:External ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners-600-×-200px-2.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230615T080000 DTEND;TZID=Europe/Brussels:20230617T180000 DTSTAMP:20260526T180902 CREATED:20230516T094713Z LAST-MODIFIED:20230516T104047Z UID:6258-1686816000-1687024800@www.europabio.org SUMMARY:3rd Hellenic Biocluster Forum DESCRIPTION:The Hellenic BioCluster is organizing its 3rd Forum on the subject of “Supporting disruptive innovation to maximize the economic and social impact of the bio-industry sector”\, scheduled to be held between 15 – 17 June 2023 at Megaron Athens International Conference Centre\, Athens\, Greece. \n\n\n\nThe 3rd HBio Forum features a 3-day\, cutting-edge programme with inspiring speakers from across the globe\, all experts in disruptive innovation\, with the aim to connect the global biotech innovation community under the sunny Athens skies. During the Forum B2B meeting opportunities will be provided between attendees and sponsors/exhibitors. \n\n\n\nThe 3rd HBio Forum will also include targeted panels of industry experts\, mentors and life sciences professionals to discuss hot topics related to investment such as raising capital and achieving success\, followed by a Pitching Competition. \n\n\n\n\nMore Details URL:https://www.europabio.org/event/3rd-hellenic-biocluster-forum/ LOCATION:Megaron Athens International Conference Centre\, Athens\, Greece CATEGORIES:External ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners-2.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230605T173000 DTEND;TZID=Europe/Brussels:20230605T183000 DTSTAMP:20260526T180902 CREATED:20230523T115247Z LAST-MODIFIED:20230524T142835Z UID:6282-1685986200-1685989800@www.europabio.org SUMMARY:EuropaBio: BIO 2023 DESCRIPTION:Round table –Biomanufacturing for health: advancing healthcare and global preparedness \n\n\n\n\n\nEuropaBio is pleased to host a round table discussion at the upcoming BIO International Convention in Boston and invites all delegates to join us to discuss on biomanufacturing for health: advancing healthcare and global prepareness. \n\n\n\nBiomanufacturing within healthcare represents an advance in therapeutic capabilities\, as ground-breaking research translates into increased diseases that can be targeted\, either for the first time or with greater efficacy\, with increasingly complex interventions becoming possible. It also brings resilience and increased environmental sustainability to strained supply chains as the world strives to modernise production systems. \n\n\n\nThe transition has significant implications for global healthcare\, competitiveness\, sustainability and resilience\, with capacity building important in all regions. \n\n\n\nThis is not just reflected in advancing healthcare for citizens but also for the world’s ability to respond to healthcare crises.  Covid demonstrated that  biomanufacturing capacity globally was called into action from multiple applications and countries for the complex manufacturing process behind vaccines. \n\n\n\nThis biomanufacturing capacity does not exist within a vacuum\, ready to be called to action when needed. It requires drug developers large and small\, public and private\, specialised manufacturers\, plus skills base\, supply chain and logistics frameworks resulting from significant investment over many years. \n\n\n\nImportantly\, a sustainable biomanufacturing framework is financed and delivered primarily through industry\, meaning that is must be integral to company strategy. This is not a guarantee\, as the global healthcare industry reacts to legislative changes and government strategies\, with major investment decisions having long term implications for the capacity and skills base within countries and regions. \n\n\n\nWhat does the world need to get right to ensure that biomanufacturing capacity grows\, to serve patients with advancing therapies and be there for coordinated emergency responses? \n\n\n\nParticipants within the round table reflect global biomanufacturing stakeholders and will discuss: \n\n\n\n\nNational policies\, incentives and strategy\n\n\n\nRegulatory and standards and alignment\n\n\n\nInternational cooperation and development\n\n\n\n\nThe output from this roundtable will be a call to global action for biomanufacturing published through EuropaBio and BIO\, with all delegates invited to contribute through the round table and follow up. \n\n\n\nAgenda \n\n\n\n10:30Welcome and introductionEuropaBio and BIO10:40Setting the scene for global biomanufacturing and the planned outcome from the round tableClaire10:45(draft) Discussion points for participants: – What does your country need to achieve for resilience through national or accessible biomanufacturing capacity?– How are regulatory frameworks adapting to an increasingly biological pipeline of medicines?– What does international cooperation need to achieve to ensure that manufacturing is actually possible during pandemic responses?– Name a priority for you to reach biomanufacturing goals in the coming years.All participants: Lead interventions on specific topics11:30Closing remarksEuropaBio and BIO\n\n\n\n\n\n\n\n \n\n\n\n\nMore information here URL:https://www.europabio.org/event/europabio-bio-2023/ LOCATION:Boston Convention & Exhibition Center\, Boston\, Massachusetts\, United States CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/Event-Banners-Website.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230601T100000 DTEND;TZID=Europe/Brussels:20230601T190000 DTSTAMP:20260526T180902 CREATED:20230321T205822Z LAST-MODIFIED:20230321T210149Z UID:6071-1685613600-1685646000@www.europabio.org SUMMARY:KNOWLEDGE FOR GROWTH 2023 DESCRIPTION:Knowledge for Growth is Europe’s finest life sciences conference.For the first time the event will take place in Antwerp.\n\n\n\nThe conference features an exciting programme providing vital insight into the global life sciences’ landscape\, one-to-one partnering\, a trade fair and more! \n\n\n\nLEARN. CONNECT. DISCOVER.\n\n\n\nThe cream of the Belgian life sciences community attends flanders.bio’s annual Knowledge for Growth business conference\, attracting decision makers from biotech\, pharma and medtech\, agricultural and chemical industry as well as investors\, universities\, top-notch research institutes\, policymakers and competence providers. \n\n\n\n\nMore information URL:https://www.europabio.org/event/knowledge-for-growth-2023/ LOCATION:Flanders Meeting & Convention Center Antwerp\, Koningin Astridplein 26\, Antwerp\, 2018\, Belgium CATEGORIES:External,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-5.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230526T100000 DTEND;TZID=Europe/Brussels:20230526T120000 DTSTAMP:20260526T180902 CREATED:20230523T140433Z LAST-MODIFIED:20230523T141004Z UID:6304-1685095200-1685102400@www.europabio.org SUMMARY:ESAB-SusChem Webinar Sustainable Chemistry DESCRIPTION:The European Society of Applied Biocatalysis (ESAB) and the European Technology Platform for Sustainable Chemistry (SUSCHEM) will held a Webinar on Sustainable Chemistry\, chaired by Pablo Domínguez de María (Sustainable Momentum SL\, ESAB Working Group Sustainable Chemistry\, SusChem Management Team) and Andrés R Alcántara (Complutense Univ of Madrid\, ESAB Working Group Sustainable Chemistry\, SusChem Board). \n\n\n\nPROGRAMME \n\n\n\n10:00 -10:30. MSc Irantzu Garmendia Aguirre\, Project Officer Safe and Sustainable by Design (SSbD)\, European Commission\, Directorate General Joint Research Centre\, Ispra\, Italy.Title: EC Recommendation for Safe and Sustainable by Design (SSbD) Chemicals Materials: scientific assessment framework policy context. \n\n\n\n10:30- 11:00. Prof. Dr. Dunming Zhu\, Tianjin Institute of Industrial Biotechnology\, Chinese Academy of Sciences\, Tianjin\, China.Title: Biocatalytic Synthesis of High Value Chemicals from Simple and/or Renewable Starting Materials. \n\n\n\n11:00-11:30. Dr. Fabrice Gallou\, Novartis Distinguished Scientist-Director Science & Technology Chemical Development\, Novartis\, Basel\, Switzerland.Title: Sustainability as a driver for innovation. \n\n\n\n11:30- 12:00. Prof. Dr. Dean Brady\, Molecular Sciences Institute\, School of Chemistry\, University of the Witwatersrand\, Johannesburg\, South Africa.Title: Biocatalysis in the synthesis of amines and amides. \n\n\n\n\nMore information here URL:https://www.europabio.org/event/esab-suschem-webinar-sustainable-chemistry/ CATEGORIES:External ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/External-Events-Banners-600-×-200px-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230517T160000 DTEND;TZID=Europe/Brussels:20230517T163000 DTSTAMP:20260526T180902 CREATED:20230516T082719Z LAST-MODIFIED:20230516T082807Z UID:6226-1684339200-1684341000@www.europabio.org SUMMARY:EU Healthcare and Pharmaceutical Policy in 2023: What You Need to Know DESCRIPTION:From the ongoing revision of the EU pharmaceutical legislation package and addressing critical supply issues to the impact of the recent Medical Device Regulation transition period extension\, the challenges in EU healthcare and pharmaceutical policy are ever-evolving. Plus\, with the implementation of critical files\, such as the European Health Data Space (EHDS) and the Substances of Human Origin (SoHo) regulation\, it’s vital for organizations in this market to stay up-to-date with the latest policy and regulatory developments. \n\n\n\nTune in on May 17 at 4 pm CEST | 10 am EDT for a 30-minute recorded webinar that will delve into the latest updates in legislation and regulation that are shaping the future of healthcare\, pharmaceutical\, and medical device industries in Europe to help you navigate the next steps in this policy landscape. \n\n\n\nExperts will discuss: \n\n\n\n\nThe ongoing revision of EU pharmaceutical legislation\n\n\n\nTackling critical supply issues in pharmaceuticals and medical devices\n\n\n\nThe impact of the Medical Device Regulation transition period extension\n\n\n\nProposed and upcoming critical files you should be monitoring\n\n\n\nThe future of EU healthcare policy in 2023 and beyond\n\n\n\n\nFeatured speakers: \n\n\n\n\nAdrien Samson\, healthcare policy & public affairs senior manager\, EuropaBio\n\n\n\nJelle Verheij\, policy analyst – health and pharmaceuticals policy\, EU Issue Tracker\n\n\n\nModerator: Geraint Edwards\, managing director of FiscalNote Brussels\n\n\n\n\n\nMore Details URL:https://www.europabio.org/event/eu-healthcare-and-pharmaceutical-policy-in-2023-what-you-need-to-know/ CATEGORIES:External,Healthcare Biotech ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/General-Promo.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230427T140000 DTEND;TZID=Europe/Brussels:20230427T151500 DTSTAMP:20260526T180902 CREATED:20230322T114230Z LAST-MODIFIED:20230412T135959Z UID:6092-1682604000-1682608500@www.europabio.org SUMMARY:EuropaBio Biomanufacturing Policy Summit 2023: Where next for Europe? DESCRIPTION:Summit outcomes and next steps \n\n\n\n\n\nOn 15th March\, EuropaBio hosted its first Biomanufacturing Policy Summit in Brussels\, with the aim of setting the vision for Europe’s global innovation\, competitiveness\, and sustainability on biomanufacturing\, while raising awareness among policy-makers. The Summit established a starting point\, a first step for a long journey that needs to be traveled by all stakeholders in Europe – SMEs\, large companies\, expert services\, and EU institutions – and which has already started in other parts of the world. \n\n\n\n80 attendees from industry\, national associations\, and stakeholders across the public and private spectrum presented\, debated\, and proposed.  In a fast-moving industrial transition\, calls for visionary policies\, enabling regulation\, and urgent action were some of the key takeaways from the summit. You can see the March 15th Summit agenda here. \n\n\n\nWould you like to find out more? \n\n\n\nJoin us on April 27 between 14:00 – 15:15 CET for a summit presentation and follow-up and add your voice to the discussion. This webinar will wrap up the main outcomes of the summit and lay the groundwork for future discussions. \n\n\n\nBiomanufacturing is key to the digital and green transitions and to securing a competitive and resilient future for Europe. Stay tuned for Europe’s future in biomanufacturing! \n\n\n\nAGENDA\n\n\n\n14:00: Welcome and introduction – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n14:10: Biomanufacturing Policy Summit report presentation – Virginia Claudio\, Sr Adviser & Programme Manager\, EuropaBio \n\n\n\nThe report presentation summarises the summit outcomes and builds policy recommendations for the development of the Biomanufacturing landscape in Europe. \n\n\n\n14:20: Report perspectives & reflections from healthcare and biotech industries\, and national associations – Sarah Moundir\, EU Public Affairs Senior Manager\, Novartis | Gwenael Servant\, Board Executive\, Abolis | Inga Matijosyte\, Vice President\, LithuaniaBIO \n\n\n\nA diverse group of stakeholders representing the wide spectrum of Biomanufacturing shares their views over the report outcomes\, as well as the priorities for their companies and organisations. \n\n\n\n14:50: Discussion and Q&A with the audience \n\n\n\nA discussion based on questions from the audience with a focus on the next steps for policy making on Biomanufacturing. \n\n\n\n15:10: Close – Closing remarks. \n\n\n\n\n\n\nRegister Here URL:https://www.europabio.org/event/europabio-biomanufacturing-policy-summit-2023-where-next-for-europe/ CATEGORIES:Biomanufacturing Platform,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/SM1-Quotes-Key-Messages-600-×-200px-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230424T100000 DTEND;TZID=Europe/Brussels:20230425T190000 DTSTAMP:20260526T180902 CREATED:20230111T144716Z LAST-MODIFIED:20230111T144717Z UID:5648-1682330400-1682449200@www.europabio.org SUMMARY:Swiss Biotech Day 2023 DESCRIPTION:The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and a fixed date in the community’s calendar. In 2022\, the conference demonstrated the impressive growth of the Swiss biotech industry and presented an exciting program with ideal networking opportunities for over 1\,100 participants across the globe. \n\n\n\nIn 2023\, the Swiss Biotech Day will again offer high-level experts from the life science industry the space to network\, discuss and discover trends in R&D\, manufacturing\, data management\, artificial intelligence and innovative financing over one and a half days. In addition\, international biotech delegations can take part in the “Global Village” to strengthen their ties with Switzerland as a biotech hub and promote cross-border investments\, public-private partnerships\, research and development collaborations and exchange of talent.  \n\n\n\nWe hope to see you in Basel on April 24-25\, 2023 in person again. \n\n\n\nWhat to expect: \n\n\n\n\nMeet 1.000+ senior experts from the life science industry\n\n\n\n70+ exhibitors and global village with international delegations from all over the world\n\n\n\nSwiss Biotech Success Stories Awards\n\n\n\nInnovative biotech start-ups and medium-sized biotech companies\n\n\n\nThematically focused panel discussions\n\n\n\nSwiss Biotech Report 2023\n\n\n\nPre-scheduled one-to-one partnering meetings\n\n\n\nGeneral Assembly of the Swiss Biotech Association\n\n\n\n\n\nMore information URL:https://www.europabio.org/event/swiss-biotech-day-2023/ LOCATION:Congress Center Basel\, Messeplatz 21\, Basel\, 4058\, Switzerland CATEGORIES:External,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230418T150000 DTEND;TZID=Europe/Brussels:20230418T160000 DTSTAMP:20260526T180902 CREATED:20230124T170639Z LAST-MODIFIED:20230406T134218Z UID:5708-1681830000-1681833600@www.europabio.org SUMMARY:Development of Orphan Biologics: Challenges and Opportunities DESCRIPTION:Webinar sponsored by Catalent \n\n\n\n\n\n\n\n\n\nThe development of therapies for rare diseases comes with distinct challenges\, including patient recruitment\, setting meaningful clinical endpoints\, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy. \n\n\n\nFor biologic products (growth factors\, monoclonal antibodies\, other complex proteins)\, development and production costs tend to be higher due to the complexity of the drug substance. To manage costs\, the clinical development and manufacturing and Chemistry\, Manufacturing and Controls (CMC) teams need to be aligned to ensure drug product is delivered on time to meet clinical trial needs. \n\n\n\nThese challenges sit within a wider regulatory and legislative framework for orphan medicinal products (OMPs) that defines whether companies can successfully develop a novel product to market and thus the decisions made for selecting therapeutics and target diseases early in development. \n\n\n\nDuring this webinar\, speakers cover aspects of clinical trial design for orphan biologics products\, key strategies for ensuring clinical trial supply throughout clinical development and the regulatory and legislative framework for delivery to patients.Key Learning Objectives \n\n\n\n\nConsiderations in identifying meaningful clinical endpoints for orphan diseases\n\n\n\nOrphan clinical trial design considerations and strategies to ensure sufficient patient recruitment\n\n\n\nManufacturing and clinical supply strategies to ensure supply of clinical trial materials while collecting data needed to support NDA submission\n\n\n\nRegulatory and legislative frameworks that guide decision making for innovation in rare diseases\n\n\n\n\nAgenda \n\n\n\n15:00: Welcome and introduction – Claire Skentelbery\, Director General EuropaBio \n\n\n\n15:05: Current Development of Orphan Drugs in Europe – Matthias Schoenermark\, Professor\, President and CEO\, SKC Beratungsgesellschaft mbH \n\n\n\nProf. Schönermark opens the session with an overview of the current status of orphan drug development in the EU. He discusses the main challenges for market entry of new orphan drugs into the EU market and highlights key recommendations to drug developers to address these challenges. \n\n\n\n15:20: Orphan Biologics and CGT Development – CMC and Clinical Trial Supply Considerations – Wai Lam Ling\, Ph.D.\, Vice President\, Science and Technology\,  Catalent \n\n\n\nDr. Ling discusses the difference in CMC challenges encountered during an orphan biologics vs CGT programme\, with a focus on product quality as the most significant hurdle to approval. She addresses manufacturing approaches to ensure regulatory compliance and factors behind a successful product\, particularly robust\, reproducible and cost-effective pathways. Finally\, supply chain liabilities are discussed\, with risks to production of biologics and their clinical supply. \n\n\n\n15:45: Successful Strategies and Business Model For Companies Bringing Their Orphan Drug To Market –Thomas Bols\, Head of Government Affairs and Patient Advocacy\, EMEA & APAC\, PTC Therapeutics \n\n\n\nThomas Bols addresses the spectrum of opportunities and barriers for innovation within orphan drug development\, particularly across different regulatory territories\, and the critical role of smaller companies in addressing unmet medical needs. He focuses on the legislative and regulatory pathways that exist in Europe for orphan drugs and the potential impact of the upcoming pharmaceutical and OMP legislation revisions for company innovation and patient benefits. \n\n\n\n16:00: Close \n\n\n\n\nRegister here URL:https://www.europabio.org/event/development-of-orphan-biologics-challenges-and-opportunities/ LOCATION:Catalent CATEGORIES:EuropaBio,External,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-5.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230418T100000 DTEND;TZID=Europe/Brussels:20230419T190000 DTSTAMP:20260526T180902 CREATED:20230110T150742Z LAST-MODIFIED:20230110T151000Z UID:5629-1681812000-1681930800@www.europabio.org SUMMARY:CEBioForum 2023 DESCRIPTION:CEBioForum is a brand that has been creating a business environment related to biotechnology for over 20 years\, organizing the most important event of this type in the industry\, dedicated to the development of biotechnology in Poland and Europe \n\n\n\nCEBioForum 2023 will take place on April 18-19 in Warsaw \n\n\n\nBecause we strongly believe that networking is the basis for building lasting business relationships\, CEBioForum 2023 is held only face-to-face\, giving you a chance to make new connections with business partners\, scientists and decision makers from the government\, who contribute to biotech development in Poland and other CEE countries. \n\n\n\nCEBioForum 2023 is more then discussion panels\, networking and the opportunity to present your company. During the conference banquete\, we will honor outstanding people and companies with CEBioForum Awards 2023. \n\n\n\nSo save the date 18-19th of April and be with us in Warsaw at CEBioForum 2023. \n\n\n\n\nMore information URL:https://www.europabio.org/event/cebioforum-2023/ CATEGORIES:External ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230328T100000 DTEND;TZID=Europe/Brussels:20230329T190000 DTSTAMP:20260526T180902 CREATED:20230320T155641Z LAST-MODIFIED:20230320T155643Z UID:6060-1679997600-1680116400@www.europabio.org SUMMARY:German Biotech Days 2023 DESCRIPTION:Germany’s largest biotech event\, the German Biotechnology Days 2023 (Deutsche Biotechnologietage\, DBT)\, will take place on March 28th and 29th in Wiesbaden. The event is the national forum for the German biotechnology industry. The DBT brings together entrepreneurs with scientists and partners from politics\, funding institutions and administration. The two-day program highlights the diverse fields of application and the potential of biotechnology\, from health research to the bioeconomy. \n\n\n\nThe German Biotechnology Days are jointly organised by BIO Deutschland and the Council of German BioRegions. The host region for 2023 is Technologieland Hessen from Wiesbaden\, and we were able to win Infectognostics Forschungscampus Jena as another partner region. \n\n\n\n\nMore information URL:https://www.europabio.org/event/german-biotech-days-2023/ CATEGORIES:External,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-6.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230315T130000 DTEND;TZID=Europe/Brussels:20230315T190000 DTSTAMP:20260526T180902 CREATED:20221114T094047Z LAST-MODIFIED:20230308T114450Z UID:5505-1678885200-1678906800@www.europabio.org SUMMARY:Biomanufacturing Platform - Policy Summit 2023 DESCRIPTION:EuropaBio’s first Biomanufacturing Policy Summit will set the vision for Europe’s global innovation\, competitiveness and sustainability through the lens of biomanufacturing and set a baseline for its understanding and recognition within policy. \n\n\n\nThe half day meeting will bring together Members and invited stakeholders from across the policy\, finance\, trade\, skills and regulatory spectrum surrounding biomanufacturing. \n\n\n\nDiscussion will address what biomanufacturing looks like across sectors and the roles played by SMEs\, large companies and expert services. The economic and skills footprint will be reviewed\, plus how it sits within Europe’s twin pillars of green and digital transition within the industrial strategy. Finally\, it can start to address how policy shapes and facilitates biomanufacture and Europe’s global position for such a transformative technology in action. \n\n\n\nFrom the first Summit\, a roadmap for biomanufacture can be developed for Europe and creation of a long term discussion platform for stakeholders through the Platform. \n\n\n\nAgenda \n\n\n\n14:00Opening plenary14:00Welcome and introduction to the Biomanufacturing Policy Summit– Claire Skentelbery\, Director General\, EuropaBio14:10Biomanufacturing in Europe’s industrial transition– Peter Dröll\, Director Prosperity\, European Commission\, DG Research and Innovation14:30Biomanufacturing as a global transition: US Executive Order for Biomanufacturing in focus– Hilary Stiss\, Director\, International Affairs\, Biotechnology Innovation Organization (BIO) 14:45Quo vadis European Biomanufacturing innovation in a competitive\, globalized world– Wojciech Nowak\, Global Senior Director\, Novartis15:00I am Biomanufacturing: examples in action ● Resilience\, sustainability and competitiveness: Biomanufacturing in daily life: Ute Schick\, Senior Vice President Research\, Development and Innovation (RDI)\, Nutrition & Care (NC-RDI)\, Evonik Operations GmbH ● Growing SMEs: Biomanufacturing in the next generation of industry: Jeroen Hofenk\, Founder and Chief Science Officer\, SwiftPharma ● The national landscape: Belgium’s economic development through biomanufacturing: Tineke Van hooland\, Deputy Secretary General Bio.be ● Advanced healthcare: The role of biomanufacturing in reaching rare diseases: Philippe Moyen\, VP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics15:30Break16:00Parallel Breakout discussionsBreakout 1 – Advanced healthcare: Role and growth in Europe● Role in Europe’s pandemic response. Scale and flexibility of manufacture – planning\, delivering\, investment● Patient access to advanced therapies (including rare diseases).● Competitiveness and economic contributor across EuropeBreakout 2 – Resilience\, competitiveness and sustainability:● Transition of industrial process for sustainability● Building resilience of supply● Innovation for competitiveness17:10Closing plenaryClosing panel discussion: Europe’s ambition and pathway for biomanufacturingStakeholders from across the biomanufacturing landscape look at the future for Europe within biomanufacturing. The industrial goals it must achieve\, the pathway towards those goals and how it can make use of the skills\, infrastructure and policy/regulatory frameworks through which Europe develops.Moderator: Kristin Schreiber (Director DG GROW)Panelists: Peter Wehrheim (Head of Unit RTD.B2)\, Kristin Thompson (COO EUREKARE)\, Nessa Fennelly (Senior Executive IBEC)\, Nicolo Giacomuzzi-Moore (Executive Director CBE JU)\, Stefaan Fiers (Head of Corporate Communication\, Public Affairs and Patient Advocacy Takeda Belgium).18:00Networking reception19:00Close\n\n\n\n \n\n\n\nSpeakers \n\n\n\n\n\n\n\n\n\n\nHilary Stiss\n\n\n\nDirector\, International Affairs\, BIO Program Director\, ICBA \n\n\n\nAs a Director for International Affairs at the Biotechnology Innovation Organization (BIO)\, Hilary is responsible for managing the industry association’s program of international advocacy and outreach for multilateral organizations. Hilary also manages the association’s engagement in Europe\, the Middle East\, North Africa\, Turkey and South Africa regions. In this position\, she engages with foreign officials in these regions to promote policies that support a strong biotechnology industry as well as to resolve policy issues relevant to the industry. Hilary also acts as Program Director for the International Council on Biotechnology Associations (ICBA). \n\n\n\n\n\n\n\n\n\n\n\n\n\nClaire Skentelbery\n\n\n\nClaire holds a PhD in biochemistry and has worked in the development of scientific networks and associations for over 15 years. She started her career as part of the Cambridge biotech cluster in the UK within the cluster business network and was a founder of the Council of European BioRegions\, a network of biotech clusters across Europe. She brought herself and CEBR to Brussels in 2009 where she also took on the role of SG for the European Biotechnology Network\, working across sectors\, organisations and countries as part of the EBN mission to facilitate partnerships. In January 2017\, Claire took up her role as DG of the Nanotechnology Industries Association which she successfully led until recently. \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Ute Schick\n\n\n\nSenior Vice President Research\, Development and Innovation\, Evonik \n\n\n\nDr. Schick has a 20-year track record in global profit and loss responsibility at CEO and Senior Manager level within Food\, Health\, Cosmetic Industry and Material Science. Before her current role with Evonik\, she held roles as SVP of Supply Chain and Business Processes and VP of new Growth Business. Prior to working at Evonik she held roles at DuPont and DSM. \n\n\n\n\n\n\n\n\n\n\n\n\n\nWojciech Nowak\n\n\n\nGroup Senior Director\, Global Governmental and Public Affairs\, Novartis International\, Switzerland.(Functional responsibility for ca. 30 countries incl. Western & Eastern Europe\, Central Asia). \n\n\n\nMulticultural\, inclusive and reflective leader who lived in 6 countries on 3 continents.Robust understanding of the global healthcare policies and life-sciences business with more than 20 years of experience in policy creation related to healthcare systems\, EU integration and global pharmaceutical market. \n\n\n\nStarted his career at the Ministry of Health (Poland) counselling policy leaders on European integration and healthcare matters\, followed by assignments in the Ministry of Health and Solidarity of the Republic of France (Paris\, France) and Health Directorate of the European Commission (DG SANCO\, Luxembourg). \n\n\n\nAfter joining private sector has been serving in a number of senior leadership roles of growingresponsibility in healthcare companies(GlaxoSmithKline\, Abbott\, Novartis) on country\, regional and global levels (Poland\, Belgium\, Switzerland). \n\n\n\nEducated in Poland\, United States\, Nederlands\, Switzerland\, with the background in political sciences\, international relations (Warsaw’s University\, Poland; European Institute of Public Administration\, Maastricht\, Nederlands) and business administration (IMD Business School Lausanne\, Switzerland) he is an expert in healthcare systems\, global healthcare policies and international business. \n\n\n\nPassionate about delivering access and best healthcare outcomes to patients around the World. \n\n\n\n\n\n\n\n\n\n\n\n\n\nTineke Van Hooland\n\n\n\nDeputy Secretary general of bio.be/essenscia \n\n\n\nTineke Van Hooland is Deputy Secretary general of bio.be/essenscia\, the Belgian federation of companies active in life sciences & biotechnologies. She’s also a board member at EuropaBio\, the European Association for Bioindustries\, from which she also chairs the NAC\, National Associations Council. Prior to this\, Tineke held several leadership positions in biopharmaceutical companies at the corporate level over the past years. She has in-depth expertise in Governmental Affairs\, Market Access\, Communication and Patient Advocacy. Tineke graduated with High Distinction as Industrial Pharmacist from Ghent University in 2003. \n\n\n\nTineke is also the founder and CEO of epic 10\, a boutique external affairs consultancy firm\, and a respected board member in various other organizations.  She is known for her dynamic and no-nonsense approach\, is a female leadership advocate and has authored a number of opinion pieces on sustainable health policy and empowering women. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Schreiber\n\n\n\nKristin Schreiber leads the Directorate Ecosystems I: Chemicals\, Food\, Retail\, Health in DG GROW\, the Directorate General for Internal Market\, Industry\, Entrepreneurship and SMEs. \n\n\n\nPrior to her current Director position\, she served as Director for Governance of the Single Market and International Affairs in DG MARKT (until 2015) and Director for SME policy in DG GROW (until March 2021). \n\n\n\nKristin Schreiber was Head of Cabinet of Employment Commissioner Vladimir Špidla\, Deputy Head of Cabinet of Internal Market Commissioner Michel Barnier and member of the Cabinets of Enlargement Commissioner Günter Verheugen and Competition Commissioner Karel Van Miert. She also served as Head of Unit for International Affairs in DG Employment and Social Affairs and was a member of the Merger Task Force of DG Competition. \n\n\n\n\n\n\n\n\n\n\n\n\n\nStefaan Fiers\n\n\n\nCorporate Communications\, Public Affairs and Patient Advocacy Takeda \n\n\n\nStefaan is Head of Corporate Communications\, Public Affairs and Patient Advocacy at Takeda Belgium\, one of the largest pharmaceutical companies in Belgium. With his team\, he secures the healthcare policy analysis\, engages with external stakeholders and coordinates the company’s communication strategy. Additionally\, he oversees Takeda’s public affairs activities in 24 mid-sized European countries. \n\n\n\nBefore joining Takeda in June 2020\, he was Director of Communications and Public Policy at the Belgian pharma industry association pharma.be and held public policy positions in the pharma industry\, at Bristol-Myers Squibb Belgium/Luxembourg and at MSD Belgium.Next to his activities at Takeda\, Stefaan is an Associate Professor in Public Affairs and Comparative Politics at KU Leuven\, a Board member of PACE (Public Affairs Community Europe)\, and the author of several books and peer-reviewed articles. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPhilippe Moyen\n\n\n\nVP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics \n\n\n\nFollowing a university focus on therapeutic systems\, followed by formulation and industrial development\, Philippe has worked across the biotechnology spectrum including Baxter Healthcare\, Fresenius Kabi\, Stallergenes Greer\, and PTC Therapeutics where he has a strong focus on operations. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Thompson\n\n\n\nVP\, Chief Business Officer \n\n\n\nKristin Thompson is a former head of strategic partnerships in microbiomes at Bioaster. Before that\, Dr. Thompson was senior BD manager at Famar and BD manager of the French biotech company DaVolterra. She worked in research at French INSERM and the University of North Carolina\, Chapel Hill. She holds a Ph.D. in molecular biology from the University of Ulm\, Germany. \n\n\n\n\n\n\n\n\n\n\n\n\n\nNicoló Giacomuzzi-Moore\n\n\n\nExecutive Director ad interim\, Circular Bio-based Industries Joint Undertaking \n\n\n\nNicoló Giacomuzzi-Moore is CBE JU’s Executive Director ad interim and Head of the Administration and Finance Unit. He has been working in European affairs for more than 20 years\, focusing on research and innovation policy\, program implementation\, and enterprise support. \n\n\n\nBefore joining BBI JU (now CBE JU) in 2016\, he worked for the European Commission’s Research Executive Agency\, where he was responsible for financial and legal support in implementing European research projects. \n\n\n\nNicoló also worked for an Italian business association dealing with industrial policy and stakeholder management at the EU level. He holds a degree in economics and international trade. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Dröll\n\n\n\nDirector for Prosperity\, Directorate-General for Research and Innovation \n\n\n\nPeter Dröll has been working in the European Commission for more than 20 years with positions in the environment\, enlargement negotiations\, industry policy\, innovation\, and research. He was a Cabinet member of Enlargement Commissioner Günter Verheugen and Head of Cabinet of the Science and Research Commissioner Janez Potočnik. \n\n\n\nSince 2010 he is at the Directorate-General of Research and Innovation where he was first responsible for Innovation and then for Industrial Technologies. Following the re-orientation of DG Research and Innovation towards sustainability\, his competencies have been enlarged to include industrial R&I agendas and business intelligence as well as knowledge valorization policies. \n\n\n\nBefore joining the European Commission in 1991\, Peter worked as a lawyer in a German law firm. Peter is a lawyer by training with a doctorate degree in German constitutional law and European law. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJeroen Hofenk\n\n\n\nFounder and Chief Science Officer\, SwiftPharma \n\n\n\nJeroen is a serial entrepreneur and scientist with a background in bioengineering and genetics. He has broad experience in CRISPR engineering and various expression platforms including microbial-\, animal cell-based\, and plants.  In the last 10 years of his career\, Jeroen has built a strong track record in plant-made-pharmaceutical manufacturing and the optimization thereof. He obtained 3 patent grants and holds 13 pending patents to his name.” \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Wehrheim\n\n\n\nHead of the Unit for the “Bioeconomy and Food System” within the Directorate General for Research and Innovation of the European Commission in Brussels \n\n\n\nWhile working for Phil Hogan\, Commissioner for Agriculture and Rural Development\, he contributed to the EU Bioeconomy Strategy. From 2010 to 2018 he was Head of the Unit for Land Use and Climate Finance in DG Climate Action. Before 2004 Peter worked at the Universities of Bonn/DE\, Maryland/US (with a Heisenberg scholarship from the German Research Foundation)\, and Kiel/DE. He received his doctoral degree in agricultural economics from the University of Giessen\, Germany \n\n\n\n\n\n\nAbout the EuropaBio Biomanufacturing Platform \n\n\n\nThe Platform has the mission to represent biomanufacturing at the highest policy levels in Europe\, to ensure that it is visible and recognised within the industrial strategy and Europe’s green and digital transitions. \n\n\n\nEuropaBio’s Biomanufacturing Platform will address the policy and wider frameworks through which biomanufacturing is delivered.  Together with members and stakeholders\, it will address how economic growth\, employment and resilience are achieved through policy\, legal frameworks and regulation at EU and national levels. \n\n\n\nThe Summit will be open to EuropaBio Members and invited stakeholders. Please contact c.skentelbery@europabio.org for further information. URL:https://www.europabio.org/event/biomanufacturing-platform-policy-summit-2023/ LOCATION:BIP Meeting Center – House of the Capital Region\, rue Royale 2-4\, Brussels\, 1000\, Belgium CATEGORIES:Biomanufacturing Platform,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/SM1-Quotes-Key-Messages-600-×-200px.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230228T110000 DTEND;TZID=Europe/Brussels:20230228T121500 DTSTAMP:20260526T180902 CREATED:20230117T135652Z LAST-MODIFIED:20230118T100150Z UID:5661-1677582000-1677586500@www.europabio.org SUMMARY:SME BioForum: Rare diseases DESCRIPTION:Rare Disease Day takes place on February 28th across the globe to raise awareness among policymakers and the public about rare diseases and their impact on patient’s lives and their families. \n\n\n\nBuilding on the latest SME BioForum on Advanced Therapy Medicinal Products (ATMPs)\, EuropaBio – the European Association for Bioindustries will mark this day by hosting an online\, invite-only SME BioForum solely dedicated to rare diseases. The event will take place from 11h00 to 12h15 CET. \n\n\n\nThe meeting is entirely SME driven. SME participants will connect with their peers\, share their experiences and discuss the current regulatory and incentives framework ahead of the revision of the pharmaceutical legislation and the legislation on orphan and pediatric medicines. \n\n\n\nIf you have any queries or want further details\, please get in touch with José Peres at j.peres@europabio.org. \n\n\n\n\nSME BioForum 2022 Report: Advanced Therapy Medicinal Products URL:https://www.europabio.org/event/sme-bioforum-rare-diseases/ CATEGORIES:Healthcare Biotech,SME Platform ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/SME-BioForum-Rare-Diseases_Event_Website.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230214T080000 DTEND;TZID=Europe/Brussels:20230215T170000 DTSTAMP:20260526T180902 CREATED:20230125T090903Z LAST-MODIFIED:20230125T090904Z UID:5720-1676361600-1676480400@www.europabio.org SUMMARY:CLIB International Conference CIC2023 DESCRIPTION:From 14 to 15 February 2023\, the CLIB International Conference will take place in Düsseldorf\, Germany\, organised by CLIB – Cluster industrial biotechnology. Under the title ” Setting sail for industrial implementation” different sessions will debate how biotechnology help achieve the climate and sustainability goals. On the first day of the CIC2023\, the focus will be on levers in this monumental transformation\, highlighting where biotechnology can really make a difference: to harness sustainable resources\, to enable innovative processes\, and ultimately to close the carbon cycle. \n\n\n\nOn the second day\, CIC2023 will host the FARMŸNG satellite event\, focusing on zero-waste biorefineries. After inputs from this CBE JU flagship\, which is constructing the first-of-a-kind vertical large-scale insect farm\, other speakers will expand the scope towards other value chains\, discussing how zero-waste biorefineries can be planned\, built\, and sustainably supplied with feedstock\, all the while closing resource loops. A final keynote will focus on investing in scale-up projects and a holistic view on sustainability. \n\n\n\nAbout 200 participants are expected\, with representatives from industry\, a large number of national and international SMEs\, research institutions and stakeholders from politics and associations. In recent years\, the CIC has established itself as a platform to initiate partnerships along value chains in the bio and circular economy. \n\n\n\nAbout CIC – CLIB International Conference \n\n\n\nThis is the annual international conference of the Cluster Industrial Biotechnology\, initiated in 2009 and now in its 13th edition. The CIC has established itself as a platform to initiate partnerships along value chains in the bio and circular economy\, each year kicking off the biotech and bioeconomy conference circle early in the year. It has about 200 participants\, with representatives from industry\, a large number of national and international SMEs\, research institutions\, and stakeholders from politics and associations. \n\n\n\nAbout CLIB – Cluster Industrial Biotechnology \n\n\n\nCLIB (Cluster Industrial Biotechnology) is an international open innovation cluster of large companies\, SMEs\, academic institutes\, and universities\, as well as other stakeholders active in biotechnology and the circular bioeconomy as a whole. The cluster comprises over 100 members with a share of about 25 % international members. The overall goal of CLIB is to network stakeholders along and across value chains and to identify new opportunities for innovation\, projects\, and business. Through this\, the cluster develops cross-sectoral biotechnological solutions for sustainable processes and products. Pertinent project areas are identified by the CLIB team in conjunction with members in an iterative process. CLIB is a non-profit association\, with its members shaping the cluster’s interests and activities. URL:https://www.europabio.org/event/clib-international-conference-cic2023/ LOCATION:Lindner Congress Hotel Düsseldorf\, Lütticher Str. 130\, Düsseldorf\, 40547\, Germany CATEGORIES:External ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/CIC2023-Banner.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230131T090000 DTEND;TZID=Europe/Brussels:20230131T123000 DTSTAMP:20260526T180902 CREATED:20230125T152351Z LAST-MODIFIED:20230125T154606Z UID:5741-1675155600-1675168200@www.europabio.org SUMMARY:EIC – EMA Info Day: Regulatory support for the development of innovative medicines and technologies DESCRIPTION:Join this online Info Day and discover the wide range of support services that the European Medicines Agency (EMA) provides to researchers and SMEs in the pharmaceutical and med-tech sectors. \n\n\n\nThe European Innovation Council (EIC)  and the European Medicine Agency (EMA) invite you to attend the EIC-EMA Info Day on January 31\, 2023 to hear about the wide range of support services provided by EMA to researchers and SMEs active in research and innovation in the pharmaceutical and med-tech sectors.   \n\n\n\nDuring the online Info Day\, you will learn on how to engage with EMA at different development milestones\, and on the range of EMA support services including those targeting gene and cell therapies\, and orphan medicines. You will also hear about the benefits to apply to the Innovation Task Force (ITF) services\, PRIME and Scientific Advice as well as practical details on how to prepare and submit applications. Moreover\, you will hear real examples of advice given through these services and will testimonials from academic researchers and companies funded by the EIC Pathfinder and Accelerator programmes on their experience with EMA services.  \n\n\n\nEIC grantees and future EIC applicants are strongly encouraged to participate. The event is also open to researchers and SMEs funded by other EU programmes.   \n\n\n\nThis event is relevant if:   \n\n\n\n\nYou are you an innovator in the health-tech sector funded by the EIC or other EU programmes. \n\n\n\nYou are in the early development stage of a medical technology or pharmaceutical\, and have not considered regulatory aspects of your innovation and support from authorities.  \n\n\n\nYour medical technology or pharmaceutical development is more advanced and you want to learn how to best apply to European Medicines Agency (EMA) services such as PRIME or Scientific Advice. \n\n\n\n\n\nMore information URL:https://www.europabio.org/event/eic-ema-info-day-regulatory-support-for-the-development-of-innovative-medicines-and-technologies/ CATEGORIES:External ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-3-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230127T100000 DTEND;TZID=Europe/Brussels:20230127T120000 DTSTAMP:20260526T180902 CREATED:20230128T220033Z LAST-MODIFIED:20230128T220327Z UID:5768-1674813600-1674820800@www.europabio.org SUMMARY:ESAB Webinar: Advances in the Analysis of Enzymatic Reactions DESCRIPTION:PROGRAMME \n\n\n\n10:00 – Prof. Dr. Andrew J. deMello\, Institute for Chemical and Bioengineering\,Department of Chemistry and Applied Biosciences\, ETH Zürich\, CH 8093 Zurich\,Switzerland \n\n\n\n10:30 – Prof. Dr. Aurelio Hidalgo\, Universidad Autonoma de Madrid\, Center for Molecular Biology “Severo Ochoa“\, 28049-Madrid\, Spain \n\n\n\n11:00 – Prof. Dr. Gerhard K.E. Scriba\, Friedrich Schiller University\, Department of Pharmaceutical Chemistry\, Jena\, Germany \n\n\n\n11:30 – Dr. Neil MacKinnon\, Principal Investigator\, NMR Spectroscopy for Metabolomics and Signalling\, Institute of Microstructure Technology\, Karlsruhe Institute of Technology\, Campus North\, 76344 Eggenstein-Leopoldshafen\, Germany \n\n\n\n  \n\n\n\n\nRegister Here URL:https://www.europabio.org/event/esab-webinar-advances-in-the-analysis-of-enzymatic-reactions/ CATEGORIES:External ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/2023-01-26-16_14_23-.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221216T140000 DTEND;TZID=Europe/Brussels:20221216T160000 DTSTAMP:20260526T180902 CREATED:20221213T132138Z LAST-MODIFIED:20221213T132140Z UID:5590-1671199200-1671206400@www.europabio.org SUMMARY:Biocatalytic Total Synthesis DESCRIPTION:14:00 – 14:30 CETHarnessing the chemistry of plant natural product biosynthesis Prof. Dr. Sarah O’ConnorDepartment of Natural Product Biosynthesis\, Max Planck Institute for Chemical Ecology\, 07745 Jena\, Germany14:30 – 15:00 CETIntermolecular Diels-Alderases: Discovery and Applications in Natural Product Synthesis Prof. Dr. Xiaoguang LeiDepartment of Chemical Biology\, College of Chemistry and Molecular Engineering\, Peking University (PKU)\, Beijing 100871\, China15:00 – 15:30 CETEnzymatic Total Synthesis Approaches to Solve Enigmatic Biosynthetic Pathways and to Generate New Natural Product Analogues Prof. Jürgen Rohr\, Ph.D.\, FRSCCollege of Pharmacy\, University of Kentucky\, Lexington\, KY\, USA15:30 – 16:00 CETBiocatalysis in ring assembly and late-stage C-H functionalization of complex molecules Prof. Dr. David H. ShermanUniversity of Michigan\, Life Sciences Institute\, Departments of Medicinal Chemistry\, Chemistry\, Microbiology & Immunology\, Ann Arbor\, Michigan\, USA\n\n\n\nThis webinar is organised by ESAB – the European Society of Applied Biocatalysis\, which aims at promoting the development of Applied Biocatalysis throughout Europe. URL:https://www.europabio.org/event/biocatalytic-total-synthesis/ ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/12/Event-Page.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221213T110000 DTEND;TZID=Europe/Brussels:20221213T121500 DTSTAMP:20260526T180902 CREATED:20221006T094946Z LAST-MODIFIED:20221207T150549Z UID:5169-1670929200-1670933700@www.europabio.org SUMMARY:SME BioForum 2022 - the voice of SMEs for a competitive\, sustainable and healthy Europe DESCRIPTION:EuropaBio – the European Association for Bioindustries is delighted to invite you to its first public SME BioForum event – “SME BioForum 2022 – the voice of SMEs for a competitive\, sustainable and healthy Europe.” \n\n\n\nThroughout 2022\, EuropaBio SME Platform\, representing Europe’s biotechnology SME community across healthcare and industrial biotechnology\, organised two inaugural SME BioForum sessions. The Platform gathered European SME executives to discuss the latest biotechnology commercial developments\, company challenges\, and how the European landscape impacts their ability to grow and deliver products and services to the market. \n\n\n\nIn our first session dedicated to Advanced Therapy Medicinal Products (ATMPs)\, SME executives discussed their main challenges to growth\, focusing on Europe’s Market fragmentation\, Regulatory pathways and other bottlenecks. The second SME BioForum session dedicated to Europe’s Green transition was hosted at EuropaBio’s flagship conference\, the European Forum for Industrial Biotechnology and the Bioeconomy in Vilnius\, Lithuania. In this session\, SME leaders discussed how European SMEs are driving Europe’s Green transition through Biomanufacturing\, Incentives for disruptive technologies and Data use and Digital applications. \n\n\n\nClosing this year\, EuropaBio will host this online event. Our SME participants and European policymakers will join us to present and debate the latest policy developments for ATMPs and Europe’s Green transition and share their recommendations for achieving a competitive\, sustainable\, healthy Europe. \n\n\n\nJoin us online for an engaging discussion on December 13\, 11h00 – 12h15 CET. \n\n\n\nSpeakers \n\n\n\n\nAhmed Bouzidi\, Managing Director Europe & VP International BD\, Trinomab Biotech\n\n\n\nLinda Dijkshoorn\, CEO\, EV Biotech\n\n\n\nPaschalia Koufokotsiou\, Pharmaceutical and Health Policy\, DG SANTE\, European Commission\n\n\n\nMiranda Lindsay-Fynn\, Commercial Director\, Bio-Sep\n\n\n\nAndré Meyer\, SME Envoy Network\, Outreach activities coordination\, DG GROW\, European Commission\n\n\n\nMaria Luísa Nolli\, EuropaBio SME Platform Chair\n\n\n\nClaire Skentelbery\, EuropaBio Director-General\n\n\n\nVivian Tseveleki\, COO\, Theracell\n\n\n\nTal Zeltzer\, CTO\, Phytolon\n\n\n\n\n\nRegister here URL:https://www.europabio.org/event/sme-bioforum-2022-the-voice-of-smes-for-a-competitive-sustainable-and-healthy-europe/ CATEGORIES:SME Platform ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/10/Event-Page.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221206T090000 DTEND;TZID=Europe/Brussels:20221207T180000 DTSTAMP:20260526T180902 CREATED:20221116T144814Z LAST-MODIFIED:20221116T145138Z UID:5525-1670317200-1670436000@www.europabio.org SUMMARY:17th European Bioplastics Conference DESCRIPTION:The European Bioplastics Conference is Europe’s leading business and discussion forum within the global bioplastics sector. More and more brands and manufacturers are embracing the potential of biopolymers\, and policy makers are increasingly streamlining their efforts to create frameworks that benefit the growth of sustainable bio-industries. Now is the time to put bioplastics at the top of the agenda of a bio-based circular economy in Europe and beyond. \n\n\n\nThe registration for the 17th European Bioplastics Conference is now open and we are excited to welcome you on 6/7 December 2022 in Berlin or online.   \n\n\n\nThe hybrid format of this year’s event will allow you to join either in person at the Maritim proArte Hotel Berlin or comfortably log-in from your home base. Both of which offer unique networking opportunities  \n\n\n\nOf course\, we will also have an excellent exhibition on- and offline. Just choose the right type of booth to give your company visibility at the conference.  \n\n\n\n\nMore details URL:https://www.europabio.org/event/17th-european-bioplastics-conference/ CATEGORIES:External ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Vilnius-Statement-Event-600-×-260px-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221201T143000 DTEND;TZID=Europe/Brussels:20221201T160000 DTSTAMP:20260526T180902 CREATED:20221117T151753Z LAST-MODIFIED:20221121T110237Z UID:5532-1669905000-1669910400@www.europabio.org SUMMARY:EuropaBio Patient BioForum 2022: Toward a Common Understanding of Unmet Medical Needs DESCRIPTION:EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. Addressing unmet medical need was outline as a central to the 2020 Pharmaceutical Strategy for Europe. One perceived shortcoming of the current legislative frameworks is insufficient stimulated development in some areas of ‘unmet medical need’ (UMN) such as antimicrobial resistance or rare diseases. The upcoming revision of the EU pharmaceutical legislation and orphan and paediatric legislation will aim at addressing “unmet medical needs”. \n\n\n\nA major hurdle to overcome is reaching a common understanding of unmet medical needs as stakeholders have different understanding of the concept based on different perceptions and expectations. Unmet medical need is scientific concept which can be used to identify patient and societal health needs and stimulate research activities. As science progresses\, and with it the knowledge to address unmet medical needs\, these needs will evolve over time from improving mortality\, modifying disease progression\, improving quality of life\, burden of the disease\, and potentially curing. \n\n\n\nBringing together multiple stakeholder groups\, including patients and industry\, the 2022 Patient BioForum is an opportunity to listen to patients’ understandings and experiences with unmet medical needs and facilitate progress towards a common understanding on unmet medical needs. \n\n\n\n \n\n\n\nSpeakers \n\n\n\n\nJoelle Khraiche\, EuropaBio\, Patient BioForum co-chair\n\n\n\n\n\nAnca Toma\, EPF\, Patient BioForum co-chair\n\n\n\n\n\nTobias S. Hagedorn\, Secretary of European Society for Phenylketonuria (ESPKU) and Managing Director of DIG PKU Germany\n\n\n\n\n\nPedro Franco\, Director Europe for Global Regulatory & Scientific Policy at Merck and Chair of EuropaBio’s OMP WG\n\n\n\n\nModerator \n\n\n\n\nAdrien Samson\, Healthcare Biotechnology Manager\, EuropaBio\n\n\n\n\n\nInvitation Only Event URL:https://www.europabio.org/event/europabio-patient-bioforum-2022-toward-a-common-understanding-of-unmet-medical-needseuropabio-patient-bioforum-2022/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Patient-BioForum-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221130T083000 DTEND;TZID=Europe/Brussels:20221130T094500 DTSTAMP:20260526T180902 CREATED:20221103T154442Z LAST-MODIFIED:20221114T101045Z UID:5462-1669797000-1669801500@www.europabio.org SUMMARY:EFIB 2022 Vilnius Statement wider launch DESCRIPTION:Industrial Biotechnology for a sustainable society: a focus for 2023 and beyond Industrial biotechnology and biomanufacturing are recognised as being part of the response to some of today’s pressing global challenges. Delivering on EU Green Deal objectives whilst strengthening resilience and independence of European industries is increasingly critical.  \n\n\n\nThe inaugural EFIB Statement of October 2021 created a baseline for industrial biotechnology and bioeconomy vision in policy\, regulatory and landscape development. The EuropaBio’s EFIB Vilnius Statement of 2022 evolves to address this long-term vision and ambition within the context of challenges and needs over the next 12 months.  \n\n\n\nWe invite you to join us for a discussion on the role and potential of enabling technologies in the EU green transition\, with a focus on priorities for the shorter term and building up to the longer term.   \n\n\n\n \n\n\n\n\nInvitation Only Event URL:https://www.europabio.org/event/efib-2022-vilnius-statement-wider-launch/ CATEGORIES:EFIB,EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Vilnius-Statement-Event-600-×-260px-1-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221118T080000 DTEND;TZID=Europe/Brussels:20221119T170000 DTSTAMP:20260526T180902 CREATED:20220719T122304Z LAST-MODIFIED:20220719T122306Z UID:5000-1668758400-1668877200@www.europabio.org SUMMARY:Scientix Conference DESCRIPTION:The 4th Scientix Conference will take place online Friday 18 and Saturday 19 November 2022. The conference\, organised by European Schoolnet\, is one of the major science education networking events in Europe. With 2\,000 places available\, the goal of the conference is to provide an overview of the challenges and opportunities in science education in Europe and highlight the potential and possibilities that the Scientix community can bring about. The Scientix conference is also a unique opportunity to learn more about different STEM education projects in Europe\, deepening connections\, generating new ideas and inspiring science educators to foster creativity and enthusiasm for STEM education and share their expertise\, knowledge\, and best practices. \n\n\n\nTeachers\, educators\, policymakers\, science education researchers\, STEM professionals\, industry representatives\, and project managers are expected to participate in the conference. The conference programme will include invited high-level plenary sessions and round tables\, as well as presentation sessions in parallel with hands-on workshops. Posters will also be made available in an interactive online format. The new format of the conference is designed to create an interactive participant experience and offer different types of networking opportunities. URL:https://www.europabio.org/event/scientix-conference/ ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/07/Event-Banners-Website.png END:VEVENT END:VCALENDAR